More than one effect in every affect.

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study.

Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis).

Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options.

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).

Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study.

Effect of Cholesterol-Lowering Variants in ANGPTL3 and APOB Genes on Liver Disease.

Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience.

Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome.